FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

l	OMB APPROVAL									
	OMB Number:	3235-0287								
l	Estimated average burde	en								
l	hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name ar		2. Issuer Name and Ticker or Trading Symbol Evoke Pharma Inc [EVOK]								eck all applic	cable)	Person(s) to Iss 10% Ov Other (s	wner					
(Last) (First) (Middle) C/O EVOKE PHARMA, INC.							3. Date of Earliest Transaction (Month/Day/Year) 03/06/2014							X Officer (give title below) Chief Medical Officer				
505 LOMAS SANTA FE DRIVE, SUITE 270																		
(Street) SOLANA BEACH	A C	CA		92075		4. If Amendment, Date of Original Filed (Month/Day/Year)							Lin	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting				
(City) (State) (Zip)														Person				
		Tab	le I - Non	-Deriv	ative	e Se	curities	s Ac	quired, I	Dis	osed o	f, or Be	neficial	ly Owned	l			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da						ear) i	2A. Deemed Execution Date, if any (Month/Day/Yea		r, Transaction Dis Code (Instr. 5)		Disposed	urities Acquired (A) sed Of (D) (Instr. 3, 4		Beneficia Owned F	es Formally (D) (Following (I) (I	orm: Direct D) or Indirect) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount	nount (A) or (D)		Reported Transact (Instr. 3	ion(s)		Instr. 4)		
		7	Table II - [uired, Di , option					Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				c	Code	v	(A)	(D)	Date Exercisabl		expiration vate	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$6.22	03/06/2015			A		45,000		(1)	0	3/05/2025	Common Stock	45,000	\$0.00	45,000	D		

Explanation of Responses:

1. The total number of shares of common stock subject to the option vests in 48 equal monthly installments over the four-year period beginning on January 1, 2015, subject to the reporting person's continued service to the Issuer through each such vesting date.

Remarks:

/s/ Matthew J. D'Onofrio, Attorney-in-fact for Marilyn R. 03/09/2015 Carlson

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.